NCT07016438招募中不适用
Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer
PharmaBio Corporation1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2025年4月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- The main measures it aims to answer safety.
研究概览
简要总结
The goal of this clinical trial is to assess safety and efficacy in patients with with Refractory skin ulcer no response to existing therapy.
The main measures it aims to answer are:
- Investigation of adverse events
- Changes in clinical testing data
- Changes in vital signs Participants will have one PAL-222 transplanted to the ulcer site. Researchers will compare before and after the transplantation to see if any safety issues are recognized.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) Patients aged 20 years or older at the time of obtaining consent (2) Patients with skin ulcers whose ulcer size has decreased by less than 50% compared to before the start of treatment even after 4 weeks or more of conservative standard treatment (3) Patients with an ulcer of 1 cm2 or more and 3 cm2 or less after debridement (4) Patients with ulcers within 5 cm from the ulcer to be treated (5) Patients with no signs of local infection in the ulcer to be treated (6) If the ulcer had the bone exposure, it needs to be within 10% of the ulcer area (7) Patients with skin reflux pressure of 30 mmHg or more at the treatment site (if the patient has an ulcer on the lower leg or foot) (8) Patients who have received a written explanation of this clinical trial from the principal investigator or clinical investigator, fully understood the information, and given their own written consent to participate in this clinical trial (9) Patients who are able to follow oral or written instructions from the principal investigator or clinical investigator
排除标准
- •(1) Patients with any of the following systemic diseases
- •Poorly controlled diabetes mellitus (HbA1c greater than 10% at the most recent examination within 28 days prior to enrollment)
- •Hypoalbuminemia (serum albumin level less than 2 g/dL)
- •Patients requiring continuous oral steroids (prednisolone equivalent greater than 10 mg per day) (2) Patients requiring general anesthesia or lumbar anesthesia during the study period for the following reasons
- •When local anesthesia is not appropriate for debridement due to scarring or hardness of the wound
- •Patients who are mentally disturbed, have involuntary movements, or are unable to keep the wound at rest during transplantation (3) Patients with a history of allergy to human serum albumin, trypsin, anesthetics used in this study, antiseptics, or covering materials (4) Patients with abnormal findings on hematology, hematochemistry, coagulation, or urinalysis at the time of screening that would be problematic for participation in the clinical trial (5) Patients with positive HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody, or syphilis serology at screening (6) Patients with severe blood disorders (if any of the following criteria are met)
- •Hemoglobin less than 10.0 g/dL
- •White blood cell count less than 3,000 /microliter
- •Neutrophil count less than 1,500 / microliter
- •Platelet count less than 75,000 / microliter (7) Patients with severe heart failure (NYHA cardiac function classification III-IV) (8) Patients with severe hepatic impairment (with a history of or complicated by fulminant hepatitis, cirrhosis, liver tumor, or any of the following criteria)
- •Total bilirubin 1.5x (upper limit of reference value) or higher
- •AST (GOP) 3.0x (upper limit of reference value) or more
- •ALT (GPT) 3.0x (upper limit of reference value) or more
- •ALP 2.5x (upper limit of reference value) or higher (9) Patients with severe renal impairment (creatinine greater than 2 mg/dL) (10) Patients diagnosed with or requiring treatment for malignancy within 5 years prior to obtaining consent (11) Pregnant or lactating women, or patients who wish to become pregnant during the study period (12) Patients whose anticoagulant or antiplatelet medication cannot be discontinued prior to the clinical trial, as determined by the attending physician of the relevant department (13) Patients with drug addiction or alcoholism (14) Patients who are currently participating in another clinical trial (15) Patients who have participated in this clinical trial once and had PAL-222 implanted (16) Patients who are judged to be inappropriate as subjects by the investigator or subinvestigator
研究组 & 干预措施
Therapeuitic group
Experimental
干预措施: Transplant surgery (Procedure)
结局指标
主要结局
The main measures it aims to answer safety.
时间窗: 28days
Safety Evaluation: Incidence, type, and severity of Adverse Events (AE)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Progression Suppression and Retinal Regression in VEGF-resistant AMDNeovascular Age-related Macular Degeneration (AMD)NCT07005323PharmaBio Corporation10
进行中（未招募）
不适用
Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)Myopic Chorioretinal AtrophyNCT05658237PharmaBio Corporation10
招募中
1 期
Phase I/IIa clinical study of PAL-222 targeting patients with myopic chorioretinal atrophyMyopic chorioretinal atrophyJPRN-jRCT2043220105Kusano Hitoshi10
进行中（未招募）
2 期
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)Hearing Loss, SensorineuralNCT05776459AudioCure Pharma GmbH210
招募中
1 期
Study of YK012 in Moderate to Severe Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE)NCT07010835Excyte Biopharma Ltd189